Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

675 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Class I HLA Alleles are associated with an increased risk of osimertinib-induced hypersensitivity.
Chen CB, Wang CW, Lu CW, Chen WT, Zhou BR, Chu CY, Hsu SF, Yang CT, Wen-Cheng Chang J, Yang CK, Wang CL, Fang YF, Hsu PC, Hua CC, Wu CE, Ko HW, Chen KC, Yang YC, Tseng HC, Cheng AY, Tseng LC, Shih FY, Hung SI, Huang CY, Chung WH. Chen CB, et al. Among authors: yang ct. J Allergy Clin Immunol Pract. 2024 Nov 4:S2213-2198(24)01110-3. doi: 10.1016/j.jaip.2024.10.027. Online ahead of print. J Allergy Clin Immunol Pract. 2024. PMID: 39505105
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial.
Zhou Q, Yu Y, Xing L, Cheng Y, Wang Y, Pan Y, Fan Y, Shi J, Zhang G, Cui J, Zhou J, Song Y, Zhuang W, Ma Z, Hu Y, Li G, Dong X, Feng J, Lu S, Wu J, Li J, Zhang L, Wang D, Xu X, Yang TY, Yang N, Guo Y, Zhao J, Yao Y, Zhong D, Xia B, Yang CT, Zhu B, Sun P, Shim BY, Chen Y, Wang Z, Ahn MJ, Wang J, Wu YL. Zhou Q, et al. Among authors: yang ct. Med. 2024 Oct 3:S2666-6340(24)00344-1. doi: 10.1016/j.medj.2024.09.002. Online ahead of print. Med. 2024. PMID: 39389055
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial.
Peters S, Cho BC, Luft AV, Alatorre-Alexander J, Geater SL, Laktionov K, Trukhin D, Kim SW, Ursol GM, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Lowery C, Mann H, Stewart R, Jiang H, Garon EB, Mok T, Johnson ML. Peters S, et al. Among authors: yang ct. J Thorac Oncol. 2024 Sep 5:S1556-0864(24)02264-0. doi: 10.1016/j.jtho.2024.09.1381. Online ahead of print. J Thorac Oncol. 2024. PMID: 39243945 Free article.
675 results